6-methoxy-2-naphthylacetic acid prodrugs

Details 6-methoxy-2-naphthylacetic acid prodrugs 6-methoxy-2-naphthylacetic acid prodrugs

2000-10-27

2003-02-25

Seidel, Marianne C. (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Radical -xh acid, or anhydride, acid halide or salt thereof...

C514S682000, C514S732000

Reexamination Certificate

active

06525098

ABSTRACT:

FIELD AND BACKGROUND OF THE INVENTION
The present invention relates to pharmaceutical compositions useful for treatment of inflammation in humans utilizing compounds that are prodrugs of 6-methoxy-2-naphthylacetic acid (hereinafter “6MNA”).
Various naphthalene derivatives are known to be useful for the treatment of inflammation and for various rheumatic and arthritic conditions. For example, Naproxen having the formula (I):
as described in U.S. Pat. No. 4,009,197 to Fried et al. Compound (I) can, however, cause severe irritation of the gastronintestinal tract at dosages only slightly greater than the excess of the therapeutic dose.
Another naphthalene derivative is nabumetone having the formula (II):
as described in U.S. Pat. Nos. 4,061,779 and 4,420,639 to Lake et al. Nabumetone works by inhibiting cyclooxygenase, an enzyme responsible for making prostaglandins which are mediators of inflammation. Nabumetone is a prodrug which undergoes hepatic biotransformation to the active component, 6-methoxy-2-naphthylacetic acid, Formula (III):
(See Haddock, R. E. et al; Metabolism of Nabumetone (BRL 14777 by various species including man,” Xenobiotica; 14(4): 327-337 (1984)). Nabumetone is commercially available as Relafen® from Smithkline Beecham, Inc. However, only about 35 percent of orally administered nabumetone is transferred in vivo into 6MNA.
It is therefore an object of the present invention to provide 6MNA prodrugs which are more readily transformed into 6MNA than nabumetone. It is believed that improvement in the body's ability to hydrolyze and solubilize the prodrug can contribute to this transformation. Thus, it is another object to improve the hydrolysis and solubility of the prodrug to provide better transformation to 6MNA.
Another concern with 6MNA and its related prodrugs is that the presence of the carboxylic acid moiety can cause stomach irritation and/or ulceration. Thus, it is another object of the present invention that provides prodrugs of 6MNA having a reduced propensity to cause stomach irritation.
SUMMARY OF THE INVENTION
As discussed above, the present invention provides therapeutically effective amounts of 6MNA prodrugs. It is believed that the 6MNA prodrug of the invention has improved hydrolysis and solubility. It is believed that the prodrugs of the invention are useful for the treatment of inflammation in humans, and can provide analgesic and antipyretic properties.
The pharmaceutical composition comprises
wherein R is selected from the group consisting of H and COR′, wherein R′ is selected from the group consisting of C
1
to C
6
alkyl, (CH
2
)
m
O(CH
2
)
n
, (CH
2
)
m
(OC
2
H
4
)
p
O(CH
2
)
n
, (CH
2
)
m
(OC
2
H
4
)
p
, (OCH
2
H
4
)
p
ONO
2
and (OCH
2
H
4
)
p
O(CH
2
)
n
wherein m is an integer from 2 to 4, and n and p are integers from 1 to 4. Alternatively, R is a therapeutic moiety.
The foregoing and other aspects of the present invention are explained in detail in the detailed description and example set forth below.


REFERENCES:
patent: 3883662 (1975-05-01), Henzl et al.
patent: 3904682 (1975-09-01), Fried et al.
patent: 3978116 (1976-08-01), Fried et al.
patent: 4009197 (1977-02-01), Fried et al.
patent: 4061779 (1977-12-01), Lake et al.
patent: 4246164 (1981-01-01), Felder et al.
patent: 4246193 (1981-01-01), Holton
patent: 4268442 (1981-05-01), Kondo et al.
patent: 4270004 (1981-05-01), Rose et al.
patent: 4327022 (1982-04-01), Bailey
patent: 4328356 (1982-05-01), Giordano et al.
patent: 4382959 (1983-05-01), Goudie
patent: 4420639 (1983-12-01), Lake et al.
patent: 4423244 (1983-12-01), Cannata et al.
patent: 4501913 (1985-02-01), Giordano et al.
patent: 4515811 (1985-05-01), Holton
patent: 4542237 (1985-09-01), Schloemer
patent: 4546201 (1985-10-01), Piccolo et al.
patent: 4550191 (1985-10-01), Castaldi et al.
patent: 4608441 (1986-08-01), Citterio et al.
patent: 4611088 (1986-09-01), Ohara et al.
patent: 4654438 (1987-03-01), Schloemer
patent: 4661524 (1987-04-01), Thomson et al.
patent: 4661525 (1987-04-01), Grazioso et al.
patent: 4670586 (1987-06-01), Yabe et al.
patent: 4670603 (1987-06-01), Piccolo et al.
patent: 4709089 (1987-11-01), Shimizu et al.
patent: 4723033 (1988-02-01), Erickson
patent: 4727102 (1988-02-01), Cannata et al.
patent: 4814494 (1989-03-01), Shimizu et al.
patent: 4851426 (1989-07-01), Ladkami et al.
patent: 4865770 (1989-09-01), Piselli
patent: 4922009 (1990-05-01), Villa et al.
patent: 4937379 (1990-06-01), Giordano et al.
patent: 4970336 (1990-11-01), Yoshioka et al.
patent: 5004832 (1991-04-01), Castaldi et al.
patent: 5068458 (1991-11-01), Dales et al.
patent: 5132466 (1992-07-01), Dales et al.
patent: 5145993 (1992-09-01), Kim et al.
patent: 5179208 (1993-01-01), Kim et al.
patent: 5200555 (1993-04-01), Kessels
patent: 5202495 (1993-04-01), Callander
patent: 5223640 (1993-06-01), Tafesh et al.
patent: 5225603 (1993-07-01), Aslam et al.
patent: 5248815 (1993-09-01), Paradies
patent: 5278333 (1994-01-01), Loosen et al.
patent: 5306833 (1994-04-01), Vallejos et al.
patent: 5426243 (1995-06-01), Lecouve
patent: 5539000 (1996-07-01), Leonard
patent: 5600009 (1997-02-01), Fritch et al.
patent: 5621000 (1997-04-01), Arena et al.
patent: 5695774 (1997-12-01), Clark
patent: 5700947 (1997-12-01), Soldato
patent: 5703073 (1997-12-01), Garvey et al.
patent: 5741938 (1998-04-01), Belmont
patent: 5750764 (1998-05-01), Marais et al.
patent: 5750793 (1998-05-01), Cannata et al.
patent: 5756851 (1998-05-01), Becnel et al.
patent: 5777170 (1998-07-01), Bellani
patent: 5780495 (1998-07-01), Del Soldato
patent: 5792886 (1998-08-01), Sabahi et al.
patent: 5847225 (1998-12-01), Ramachandran et al.
patent: 5861538 (1999-01-01), Theriot
patent: 5874614 (1999-02-01), Phan et al.
patent: 5907069 (1999-05-01), Becnel et al.
patent: 5955635 (1999-09-01), Cabri et al.
patent: 6057347 (2000-05-01), Garvey et al.
patent: WO 9404484 (1994-03-01), None
patent: WO 9412463 (1994-06-01), None
patent: PCT/EP95/01233 (1995-04-01), None
patent: WO 9731654 (1997-09-01), None
“4-(6-Methoxy-2-naphtyl)butan-2-one and related analogs, a novel structural class of antiinflammatory compounds”, Goudie et al, J. Med. Chem, 1978, 21(12), 1260-4; Abstract.*
Wadhwa, et al., “Glycolamide esters of 6-methoxy-2-napthtylacetic acid as potential pro-drugs-Synthetic and spectral studies”, Indian Journal of Chemistry, vol. 34B, May 19995 (pp. 408-415).
Mangan, et al., “Preclinical Overview of Nabumetone”, The American Journal of Medicine, vol. 83 (suppl. 4B), Oct. 1987 (pp. 6-10).
Jeremy, et al., “Effects of Prodrug Nabumetone, and its Active Metabolite, 6-MNA, on Human and Rat Gastric Mucosal Prostanoids and Platelet Function”, Drugs 40 (Suppl. 5), 1990 (pp. 53-56).
Benoni, et al., “Plasma Concentrations and Pharmacokinetic Parameters of Nitrofenac Using a Simple and Sensitive HPLC Method”, Journal of Pharmaceutic Sciences, vol. 84, No. 1, Jan. 1995 (pp. 93-95).
Brett, et al., “Nabutemone, Evidence for the Lack of Enterohepatic Circulation of the Active Metabolite 6-MNA in Humans”, Drugs 40 (Suppl. 5), 1990 (pp. 67-70).
Hellberg et al., “Novel Esters and Amides of Nonsteroidal Antiinflammatory Carboxylic Acids as Antioxidants and Antiproliferative Agents”,J. Med. Chem.,42(2): 267-276 (1999).
Martha Hyneck, “An Overview of the Clinical Pharmacokinetics of Nabumetone,”The Journal of Rheumatology, 19(36): 20-24 (1992).
International Search Report corresponding to PCT/US 00/29757: date of mailing: Sep. 14, 2001.
Paris et al., “Glycerides as Prodrugs. 4. Synthesis and Antiinflammatory Activity of 1,3-dialkanoyl-2-arlaklanoylglycerides”,Eur. J. Med. Chem.,17(2): 193-195 (1982).
Stephen L. Dahl, “Nabumetone: A ′Nonacidic′Nonsteroidal Antiinflammatory Drug”,The Annals of Pharmacology, 27: 456-463 (Apr.1993).
Soma et al., “Disposition and Excretion of 6-Methoxy-2-Naphthylacetic Acid, the Active Metabolite of Nabumetone in Horses”,AJVR, 57(4): 517-521 (Apr. 1996).
International Search Report corresponding to PCT/US 00/41692; Date of Mailing: Oct. 11, 2001.

Affiliated with

Also associated with

Rating

6-methoxy-2-naphthylacetic acid prodrugs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 6-methoxy-2-naphthylacetic acid prodrugs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 6-methoxy-2-naphthylacetic acid prodrugs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3179630